Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.47 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352877 | 1.00 | CHEK1 (0.47) | CHEK1TLK2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6279537 | 0.80 | MAPT (0.50) | CHEK1ALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL6358112 | 0.80 | MAPT (0.50) | CHEK1ALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL6355324 | 0.79 | CHEK1 (0.34) | CHEK1MAPTSMN1; SMN2GAALRRK2 | |
| SCHEMBL6355327 | 0.79 | CHEK1 (0.34) | CHEK1MAPTSMN1; SMN2GAALRRK2 | |
| SCHEMBL6355160 | 0.79 | CHEK1 (0.48) | CHEK1TLK2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6355162 | 0.79 | CHEK1 (0.48) | CHEK1TLK2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6358042 | 0.77 | ALOX5 (0.41) | TLK2ALDH1A1MAPTGAATTR | |
| SCHEMBL6358044 | 0.77 | ALOX5 (0.41) | TLK2ALDH1A1MAPTGAATTR | |
| SCHEMBL11116203 | 0.76 | MAPT (0.57) | CHEK1ALDH1A1MAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | CHEK1 4118/4885TLK2 658/4885ALDH1A1 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.